EUVIMEDEUVIMED entdecken
Multizentrische Studie

Real-world efficacy and safety of dupilumab for paediatric atopic dermatitis: a multicentre retrospective study

Eitan Pirov iD, Vered Molho-Pessach, Eran Cohen-Barak, Jen A Barak Levitt, Aviv Barzilai, Jonathan Bar, Yael Renert-Yuval, Efrat Bar-Ilan, Rivka Friedland, Shoshana Greenberger iD

Clinical and Experimental Dermatology · 2025

DOI: 10.1093/ced/llae406 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical and Experimental Dermatology, 2025. Verfasst von Eitan Pirov und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Dermatology Unit, Department of Dermatology, Sheba Medical Center, Israel. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized, Dermatologic Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Real-world data regarding the use of dupilumab in children with atopic dermatitis (AD) are limited.

Objectives

To evaluate the real-world efficacy of dupilumab in children with moderate-to-severe AD over an extended follow-up period.

Methods

This was a retrospective study of patients (≤ 18 years) with moderate-to-severe AD treated with dupilumab in four Israeli tertiary centres. Efficacy and safety were assessed using descriptive statistics.

Results

In total, 230 patients were included in the analysis [age 9.9 years (SD 4.3), male/female 1 : 1 ratio)]. Of them, 59.6% (137/230) had ≥ 1 atopic comorbidity. The follow-up duration ranged from 2 to 248 weeks, with a median of 52 weeks (interquartile range 24–96). Within 12 weeks of treatment, 41.7% (68/163) of patients had reached Investigator Global Assessment 0–1. The mean body surface area was reduced from 58.0% (SD 20.5%) at baseline to 27.8% (SD 20.2%) at 12 weeks. The average Pruritus Numeric Rating Scale score was reduced from 7.9 (SD 2.2) at baseline to 2.3 (SD 2.8) at 12 weeks. Adverse events, in 210 patients, included conjunctivitis in 34 patients (16.2%), injection-site reactions in 11 patients (5.2%) and dupilumab-associated head and neck dermatitis in 6 patients (2.9%). Overall, 26 of 210 patients (12.3%) discontinued the treatment: 9 of the 26 patients (35%) because of adverse events and 15 patients (58%) because of inadequate efficacy. The overall probability of dupilumab survival at 52 weeks was 94.0%.

Conclusions

Real-world data presented here for 230 paediatric and adolescents with moderate-to-severe AD reinforce dupilumab’s efficacy and safety and highlight dupilumab’s high survival rate after 1 year of treatment in the paediatric population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAntibodies, Monoclonal, HumanizedDermatologic AgentsHumansMaleRetrospective StudiesFemaleChildTreatment OutcomeAdolescentChild, PreschoolSeverity of Illness IndexIsrael

Substanzen

dupilumabAntibodies, Monoclonal, HumanizedDermatologic Agents

Autor:innen und Institutionen

  • Pediatric Dermatology Unit, Department of Dermatology, Sheba Medical Center, Israel.
  • Faculty of Medicine, Hebrew University of Jerusalem, Pediatric Dermatology Service, Department of Dermatology, Hadassah Medical Center, Jerusalem, Israel.
  • Department of Dermatology, Emek Medical Center, Afula, Israel.
  • Ruth and Bruce Rappaport Faculty of Medicine, Technion Institute of Technology, Haifa, Israel.
  • Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.
  • Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

ORCID-Profile: Eitan Pirov, Shoshana Greenberger

Zitieren

APA

Pirov, E., Molho-Pessach, V., Cohen-Barak, E., Barak Levitt, J. A., Barzilai, A., Bar, J., Renert-Yuval, Y., Bar-Ilan, E., Friedland, R., & Greenberger, S. (2025). Real-world efficacy and safety of dupilumab for paediatric atopic dermatitis: a multicentre retrospective study. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llae406

Vancouver

Pirov E, Molho-Pessach V, Cohen-Barak E, Barak Levitt JA, Barzilai A, Bar J, et al. Real-world efficacy and safety of dupilumab for paediatric atopic dermatitis: a multicentre retrospective study. Clinical and Experimental Dermatology. 2025. doi:10.1093/ced/llae406

BibTeX
@article{Pirov2025,
  author = {Pirov, Eitan and Molho-Pessach, Vered and Cohen-Barak, Eran and Barak Levitt, Jen A and Barzilai, Aviv and Bar, Jonathan and Renert-Yuval, Yael and Bar-Ilan, Efrat and Friedland, Rivka and Greenberger, Shoshana},
  title = {Real-world efficacy and safety of dupilumab for paediatric atopic dermatitis: a multicentre retrospective study},
  journal = {Clinical and Experimental Dermatology},
  year = {2025},
  doi = {10.1093/ced/llae406}
}
Kostenlos starten →